Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-022-02121-z
Updates & Corrections
-
Clarification 12 August 2022: An earlier version of this story inadvertently referred to Paxlovid ‘resistance’ instead of Paxlovid rebound.
References
Deo, R., et al. Preprint at medRxiv https://doi.org/10.1101/2022.08.01.22278278 (2022).
Dai, E. Y. et al. Preprint at medRxiv https://doi.org/10.1101/2022.08.04.22278378 (2022).
Charness, M., et al. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-1588371/v3 (2022).
Soares, H. et al. Preprint at Research Square https://doi.org/10.21203/rs.3.rs-1720472/v2 (2022).
Najjar-Debbiny, R., et al. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciac443 (2022).